Glipizide suppresses prostate cancer progression in the TRAMP model by inhibiting angiogenesis
Qi C, et al.
Scientific reports, 6(20), 27819-27819 (2016)
Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment
Karnes JH, et al.
The Pharmacogenomics Journal, 13(5), 430-430 (2013)
Greg L Plosker
Drugs, 72(17), 2289-2312 (2012-11-23)
Dapagliflozin (Forxiga®) is the first in a novel class of glucose-lowering agents known as sodium-glucose co-transporter-2 (SGLT2) inhibitors and is used in the treatment of patients with type 2 diabetes. By inhibiting the transporter protein SGLT2 in the kidneys, dapagliflozin...
Korbinian Löbmann et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 81(1), 159-169 (2012-02-23)
The objective of this study was to prepare a co-amorphous drug/drug combination between two BCS class II drugs, simvastatin (SVS) and glipizide (GPZ). This pharmacologically relevant combination of two drugs could produce a promising candidate for formulations intended for combination...
KCNJ1 inhibits tumor proliferation and metastasis and is a prognostic factor in clear cell renal cell carcinoma
Guo Z, et al.
Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine, 36(2), 1251-1259 (2015)